A widely used over-the-counter painkiller long promoted as benign in pregnancy is now under renewed scrutiny after a European study linked prenatal exposure to measurable changes in the reproductive organs of infant girls.
According to Western Journal, researchers with the Copenhagen Analgesic (COPANA) study in Denmark reported that baby girls whose mothers used paracetamol known in the United States and Japan as acetaminophen and the active ingredient in Tylenol while pregnant were more likely to have smaller ovaries, fewer ovarian follicles, altered reproductive hormone levels and reduced uterine size at three months of age. The findings, while not definitive, raise uncomfortable questions about a drug that public health authorities and corporate manufacturers have long treated as the safe alternative to other painkillers, even as up to 65 percent of American women report using it at some point during pregnancy.
The Danish team enrolled 685 women during the first trimester and later examined 302 of their healthy infant daughters when the girls reached three months old. Researchers tracked paracetamol exposure through bi-weekly maternal self-reports and by measuring the drug in urine samples, allowing for a more detailed picture of use than many earlier observational studies.
Despite the striking associations, the authors were careful to stress that the long-term implications remain unclear and that more research is needed before firm conclusions can be drawn. The report noted that whether these early-life differences have long-term clinical relevance, including effects on reproductive lifespan, remains uncertain and that only extended follow-up can determine whether these early markers translate into real-world fertility problems.
Study co-author Dr. Margit Bistrup Fischer underscored that the research should not be used as a blunt instrument to frighten expectant mothers away from necessary treatment. Our study does not suggest that pregnant women should stop using paracetamol when it is genuinely needed, particularly for fever or significant pain, Fischer told the Daily Caller News Foundation. However, it does contribute to a growing signal that we should pay closer attention to use during pregnancy, especially because paracetamol is an over-the-counter medicine that is often perceived as entirely risk-free.
The drugs ubiquity is part of what alarms many observers on the right who have long warned about the cozy relationship between regulators, pharmaceutical giants and the medical establishment. In addition to being the primary active ingredient in Tylenol products, acetaminophen is among the most common active drugs in the United States, according to the companys own website, meaning any underappreciated risk could affect millions of families who trusted official assurances.
Fischer said the Danish team hopes its work will spur a broader scientific and regulatory response rather than be dismissed as an outlier. We hope this study will stimulate further research in this area as well as discussions among researchers, clinicians, and regulatory authorities, she continued. While our findings add to a growing body of evidence, there is a need for larger studies with longer follow-up to determine whether the associations we observed with markers of female reproductive development and ovarian reserve translate into differences in reproductive health later in life.
At the same time, Fischer sought to calm fears among mothers who may now be second-guessing decisions made under medical guidance. She emphasized that any women who have used paracetamol during pregnancy should not be alarmed by the studys findings and that the data cannot be used to predict outcomes for any individual child.
Our study examined associations at the population level and cannot predict outcomes for any individual woman or child, she explained. Many women who used paracetamol during pregnancy had daughters whose ovarian measurements were similar to those of daughters born to women who did not use paracetamol. Paracetamol remains an important treatment option during pregnancy, particularly for conditions such as high fever or significant pain, where treatment may be important for both maternal and fetal health.
The authors also highlighted the novelty of their work in the human context, even as it echoes a troubling pattern seen in laboratory research. This is the first human study specifically designed to investigate whether prenatal paracetamol exposure is associated with markers of ovarian development in daughters, according to the report, which added that the study cannot prove that paracetamol directly caused these differences, the findings are consistent with results from animal studies.
Multiple experimental animal studies have suggested that offspring of mothers given the drug while pregnant had smaller ovaries and fewer eggs, CNN reported, reinforcing concerns that what has been observed in rodents and other models may not be entirely irrelevant to humans. For conservatives skeptical of technocratic assurances, the convergence of animal and human data is yet another reason to question the reflexive safe and effective mantra that often accompanies mass medication.
The American College of Obstetricians and Gynecologists, a powerful professional body that has frequently aligned with progressive positions on abortion and other cultural issues, responded with a cautious but notably non-dismissive statement. While this study reports associations between prenatal acetaminophen exposure and certain measures of ovarian and uterine development in offspring, as the authors themselves state, the clinical significance of these findings is uncertain or unknown, an ACOG spokesperson told the DCNF in a statement. The oldest participants evaluated were adolescents, and the study cannot determine whether the observed differences are associated with future reproductive outcomes such as fertility, ovulatory function, reproductive lifespan, or other measures of reproductive health.
The group also pointed to methodological limits that are common in observational research but do not erase the signal emerging from multiple lines of evidence. The authors also acknowledge important limitations, including substantial inter-individual variability in these measures and the inability to establish causality from an observational study, the ACOG spokesperson added, effectively conceding that while the study is not the final word, it cannot simply be waved away.
Beyond reproductive development, acetaminophen has already been implicated in a separate and arguably even more alarming area: neurodevelopmental disorders such as autism and ADHD. Janssen, the pharmaceutical company that makes Tylenol, privately acknowledged the potential connection between prenatal use of the drug and such conditions in children several years ago, the DCNF first reported in September 2025, raising serious questions about what the company knew and when it chose to inform the public.
The weight of the evidence is starting to feel heavy to me, Rachel Weinstein, U.S. director of epidemiology for Janssen, the pharmaceutical arm of Johnson & Johnson, said in 2018, the DCNF reported, suggesting that internal experts were far less sanguine than the marketing and public-relations messaging that continued to portray the drug as a low-risk staple. For those who believe in corporate accountability and transparency, that admission underscores the need for robust oversight rather than blind trust in multinational drug makers.
Federal regulators have been slow to act, but even the U.S. Food and Drug Administration has now been forced to acknowledge the accumulating data. The agency issued a notice to physicians regarding the use of acetaminophen during pregnancy on Sept. 22, 2025, stating that in recent years, evidence has accumulated suggesting that the use of acetaminophen by pregnant women may be associated with an increased risk of neurological conditions such as autism and ADHD in children.
The FDA further warned that some studies have described that the risk may be most pronounced when acetaminophen is taken chronically throughout pregnancy to childbirth, according to the agencys letter. These concerns may be magnified by the fact that a very young childs liver may still be developing and thus a childs ability to metabolize the drug may be limited.
Taken together, the Danish findings on female reproductive development and the broader body of research on neurodevelopmental risks point to a common theme: a supposedly harmless, widely used drug may carry underappreciated dangers when used during the most vulnerable stages of human life. For families, physicians and policymakers who value the sanctity of life and the duty to protect children, the emerging evidence argues for a far more cautious, informed approach to acetaminophen use in pregnancy, one that prioritizes transparency, parental consent and genuine risk-benefit analysis over pharmaceutical convenience and bureaucratic complacency.
Login